Skye Bioscience said Monday that its obesity drug candidate failed to help patients lose significant weight in a mid-stage study, hampering the biotech’s efforts to bring forward a drug with a controversial mechanism.

The medicine, an antibody that blocks CB1 receptors, led patients to lose on average 1.5% of their weight over 26 weeks, but it wasn’t a statistically significant improvement versus placebo.

Skye said its preliminary analysis showed lower than expected drug exposure, potentially indicating the need to test higher doses. It’s continuing to assess the data to determine possible next steps, including an additional Phase 2 study.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page